Aravive, Inc. (ARAV)

Market Cap	10.37M
Revenue (ttm)	7.00M
Net Income (ttm)	-39.85M
Shares Out	73.56M
EPS (ttm)	-0.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,230,662
Open	0.140
Previous Close	0.141
Day's Range	0.134 - 0.145
52-Week Range	0.110 - 2.460
Beta	2.30
Analysts	Hold
Price Target	5.13 (+3,462.5%)
Earnings Date	Dec 19, 2023

About ARAV

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 21, 2014
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: ARAV

Financial Performance

In 2022, Aravive's revenue was $9.14 million, an increase of 22.78% compared to the previous year's $7.44 million. Losses were -$76.32 million, 94.9% more than in 2021.

Analyst Forecast

According to 6 analysts, the average rating for ARAV stock is "Hold." The 12-month stock price forecast is $5.13, which is an increase of 3,462.50% from the latest price.

Price Target

$5.13

(3,462.50% upside)

Analyst Consensus: Hold